Colloidal systems for antiviral drugs encapsulation: towards accessible and long-term release treatments for neglected diseases

SEPULVEDA CLAUDIA S.; CASTAÑEDA CATAÑA, MAYRA ALEJANDRA; SÁNCHEZ DOMINGUEZ MARGARITA; PÉREZ, OSCAR EDGARDO

Monterrey

Congreso; LatinXchem; 2020

ASC

The emergence of virus resistant to antiviral drugs has generated the search for and development of new antiviral strategies. An ideal therapeutic target to prevent the development of drug resistance is based on using cellular factors that participate in viral infection as potential antiviral targets. The advantages of this approach are fundamentally based on the feasibility of obtaining active broad-spectrum drugs against different pathogenic viruses, as well as the possibility of avoiding the appearance of antiviral resistance, one of the key problems of chemotherapy today. Recent efforts have focused on finding and characterizing cellular metabolic inhibitors as broad-spectrum antivirals to attack with minimal cytotoxicity. Mycophenolic acid (MPA) is a non-nucleoside, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). It is well known for its effects as an immunosuppressant and against the multiplication of various viruses (Dengue, Zika Junín). However, MPA presents difficulties in its administration, its low assimilation, 93% of the dose recovered in the urine and 6% in the feces, another problem is its rapid elimination from the body with a period of between 16 to 18 h. The resolution to this problem we proposed to encapsulate MPA in nanoparticles that are biodegradable and biocompatible, thus increasing its bioavailability. Using the PIC (phase investment composition) method, we obtain nanoemulsions as a template for obtaining polymeric nanoparticles capable of encapsulating MPA. We used the PLGA 75:25 polymer (4000-15000 MW) at 4% w / w in ethyl acetate, the aqueous phase was PBS 0.16 M. The Nanoparticles obtained have a diameter of 29 ± 7 nm, with an encapsulation efficiency 25%.